author-photo

Anna Kondic

Merck & Co.

13

Papers

480

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (82)
Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

2017
Show All
- Source
- Cite
- Save
Citations (20)
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma

2017
Show All
- Source
- Cite
- Save
Citations (42)
Evaluation of dosing strategy for pembrolizumab for oncology indications

2017 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (115)
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (77)
Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Abstract CT112: Exposure-response analysis of pembrolizumab in patients with advanced melanoma and non-small cell lung cancer enrolled in KEYNOTE-001, -002, and -006

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
3344 Relationship between pembrolizumab exposure and efficacy/safety in 1016 patients (pts) with advanced or metastatic melanoma

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

2014 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (37)
State-of-the-Art Pharmacometric Models in Osteoporosis

2014
Show All
- Source
- Cite
- Save
Citations (0)